tocilizumab-anoh 180 MG/ML per 0.9 ML Auto-Injector

RxCUI
2705435
RxNorm name
tocilizumab-anoh 180 MG/ML per 0.9 ML Auto-Injector
Display name
tocilizumab-anoh 180 MG/ML per 0.9 ML Auto-Injector
Full name
tocilizumab-anoh 180 MG/ML per 0.9 ML Auto-Injector
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:00

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761420Avtozmatocilizumab-anoh351(k) InterchangeableRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
AVTOZMATOCILIZUMABCELLTRION USA, Inc.581c288f-8015-40ef-a4c3-683c96db193d2026-07-27Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2705435

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
581c288f-8015-40ef-a4c3-683c96db193dtocilizumab-anoh 162 MG in 0.9 ML Auto-Injector [PSN] · 0.9 ML tocilizumab-anoh 180 MG/ML Auto-Injector [SCD] · tocilizumab-anoh 162 MG per 0.9 ML Auto-Injector [SY] · tocilizumab-anoh 180 MG/ML per 0.9 ML Auto-Injector [SY]44These highlights do not include all the information needed to use AVTOZMA safely and effectively. See full prescribing information for AVTOZMA. AVTOZMA ® (tocilizumab-anoh) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 AVTOZMA (tocilizumab-anoh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful20260123
60381a7e-d7ae-4384-925d-c19c418d1663tocilizumab-anoh 162 MG in 0.9 ML Auto-Injector [PSN] · 0.9 ML tocilizumab-anoh 180 MG/ML Auto-Injector [SCD] · tocilizumab-anoh 162 MG per 0.9 ML Auto-Injector [SY] · tocilizumab-anoh 180 MG/ML per 0.9 ML Auto-Injector [SY]44These highlights do not include all the information needed to use TOCILIZUMAB-ANOH safely and effectively. See full prescribing information for TOCILIZUMAB-ANOH. TOCILIZUMAB-ANOH injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 Tocilizumab-anoh is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful dif20260123